ClinicalTrials.gg
CompletedNCT07169188Updated Jan 21, 2026

A Clinical Study Investigating the Efficacy of an Experimental Toothpaste Containing Stannous Fluoride in Improving Gingival Health

An interventional study of Test Fluoride Toothpaste and Colgate Cavity Protection Toothpaste in Dental Plaque and Gingivitis, sponsored by HALEON. Completed at 1 site in Canada. Open to participants aged 18 Years to 70 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-01-21.

Sponsored by HALEON · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
154
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Study summary

The aim of this study is to evaluate the ability of an experimental toothpaste, containing 0.454 percent (%) Stannous Fluoride (SnF2) to improve gingival health and reduce plaque accumulation compared to a regular fluoride toothpaste (reference dentifrice) in participants with localized, plaque-induced, gingivitis.

Read the detailed description

This will be a single-center, 12 weeks, randomized, controlled, examiner-blind, 2 treatment arms, parallel group design clinical study to evaluate the efficacy of an experimental toothpaste containing 0.454% SnF2, used twice daily in reducing gingivitis and plaque accumulation in a population with clinically measurable levels of gingivitis. The clinical efficacy of the experimental toothpaste will be compared with a reference dentifrice, a commercially available, regular fluoride toothpaste. Additionally, unstimulated saliva samples will be collected from a sub-set of the randomized participants pre-brushing and at 15, 30, 60 and 120 minutes post-brushing which will be analyzed for tin concentration to investigate the retention of the stannous [tin (II)] ion within the oral cavity. Approximately 160 participants will be randomized to ensure approximately 144 evaluable participants complete the study.

02

Conditions studied

  • Dental Plaque
  • Gingivitis
03

In context

Dental Plaque

354 studies on the registry are indexed under Dental Plaque; 60 are open to participants now.

This study's enrollment of 154 is above the median of 55 across 317 interventional studies indexed under Dental Plaque.

Browse Dental Plaque studies →

Lead sponsor

HALEON is the lead sponsor of 65 studies on the registry; 10 are open to participants now.

Of its 6 completed or terminated interventional studies of FDA-regulated products, 2 (33%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant has provided a signed and dated document indicating that they have been informed of all pertinent aspects of the study before any assessment is performed.
  2. Participant is of either biological sex and any gender.
  3. Participant is, at the time of screening, aged 18-70 years, inclusive.
  4. Participant is willing and able to comply with scheduled visits, treatment plan and all study procedures and Lifestyle Considerations.
  5. Participant is in good general and mental health with, in the opinion of the investigator or medically qualified designee, no or relevant abnormalities in medical history or upon oral examination, or condition, that would impact the participant's safety, wellbeing or the outcome of the study, if they were to participate in the study, or affect the individual's ability to understand and follow study procedures and requirements.
  6. Participant with oral health that meets all the following:

    1. At Visits 1 and 2, has at least 20 natural, permanent teeth (excluding 3rd molars) with at least 40 evaluable surfaces for MGI and TPI assessments.
    2. At Visit 2, has, in the opinion of the examiner, localized plaque-induced gingivitis with 10-30% bleeding sites from the BI assessment and with an overall TPI score >= 1.5.

Exclusion criteria

Exclusion Criteria:

  1. Participant is an employee of the site, either directly involved in the conduct of the study or a member of their immediate family; or an employee of the investigational site otherwise supervised by the investigator; or a Haleon employee directly involved in the conduct of the study or a member of their immediate family.
  2. Participant has participated in other studies (including non-medicinal studies) involving investigational product(s) within 30 days prior to study entry and/or during study participation.
  3. Participant with, in the opinion of the investigator or medically qualified designee, an acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with study participation or investigational product administration or may interfere with the interpretation of study results and, in the judgment of the investigator or medically qualified designee, would make the participant inappropriate for entry into this study.
  4. Participant has any other clinical serious or unstable conditions (example, cardiovascular diseases, diabetes, liver disorders, and kidney disorders) which could have affected study outcomes and/or participant safety.
  5. Participant is breast feeding or is pregnant (self-reported) or intending to become pregnant over the duration of the study.
  6. Participant with known or suspected intolerance or to the study materials (or closely related compounds) or any of their stated ingredients.
  7. Participant is unwilling or unable to comply with the Lifestyle Considerations described in this protocol.
  8. Participant is a current or ex (stopped within 6 months of Screening) nicotine user, example, smokes, vapes or uses smokeless forms of tobacco such as chewing tobacco, gutka, pan containing tobacco, snus, tobacco pouches etc.
  9. Participant has diagnosed xerostomia or is taking any medication or has a condition, that in the opinion of the investigator, is causing xerostomia.
  10. Participant has a medical condition (example, bleeding disorder) which could directly influence gingival bleeding or could affect study outcomes and/or participant safety.
  11. Participant who has a recent history (within the last year) of alcohol or other substance abuse.
  12. Participant who has a severe oral condition (example, acute necrotizing ulcerative gingivitis or oral or peri-oral ulceration including herpetic lesions) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant/examiner if they participate in the study.
  13. Participant has a tongue or lip piercing, or any other oral feature that, in the opinion of the investigator, could interfere with the proper usage of a toothbrush or with correct application of study products.
  14. Participant has/is using the following medications:

    1. Any antibiotic medication within 28 days prior to screening, or at any time during the study.
    2. Any anti-bacterial toothpaste/mouthwash (example, chlorhexidine) or other oral care product within 2 weeks of Screening that, in the opinion of the investigator or dentally qualified designee, could affect plaque formation or gingival health.
    3. Systemic medication (example, anti-inflammatories, anticoagulants, , traditional/ herbal remedy etc) within 2 weeks of screening or at any point in the study, which, in the opinion of the Investigator, could affect plaque/gingival condition (example, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).
    4. A participant currently taking a systemic medication (example, anti-inflammatory, anticoagulant, immunosuppressants) or traditional/ herbal remedy which, in the opinion of the Investigator, could affect plaque/ gingival condition (example, ibuprofen, aspirin, warfarin, cyclosporin, phenytoin, calcium channel blockers).
  15. Participant demonstrating the following dental conditions:

    1. Signs of active periodontitis (site with probing depth over 3 mm)
    2. Is receiving or has received treatment for periodontal disease (including surgery) within 12 months of Screening.
    3. Has gingivitis, which in the opinion of the investigator, is not expected to respond to treatment with an over the counter (OTC) dentifrice.
    4. Has active caries that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
    5. Has dentures (partial or full) or an orthodontic appliance (bands, appliances, or fixed/ removable retainers).
    6. Has received orthodontic therapy within 3 months of Screening.
    7. Has numerous restorations in a poor state of repair.
    8. Has any dental condition (example, overcrowding) that could, in the opinion of the investigator, compromise study outcomes or the oral health of the participant if they participate in the study.
    9. Has had dental prophylaxis or tooth bleaching within 12 weeks of Screening.
    10. Has high levels of extrinsic stain or calculus deposits, in the opinion of the investigator, that could have interfered with plaque assessments.
  16. Participant who has previously been enrolled in this study.
  17. Participant who, in the opinion of the investigator or medically qualified designee, should not participate in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Investigator)
Enrollment
154 participants (actual)

Study arms

  • Experimental
    Test Toothpaste

    Participants will brush their teeth with full ribbon of test toothpaste applied on head of toothbrush provided for one timed minute twice a day (morning and evening) for 12 weeks.

    Drug: Test Fluoride Toothpaste

  • Active comparator
    Reference Toothpaste

    Participants will brush their teeth with full ribbon of reference toothpaste applied on head of toothbrush provided for one timed minute twice a day (morning and evening) for 12 weeks.

    Drug: Colgate Cavity Protection Toothpaste

Interventions

  • DrugTest Fluoride Toothpaste

    Toothpaste containing 0.454% SnF2, 0.3% zinc chloride (ZnCl2) and 1% alumina.

  • DrugFluorophosphateStudies of FluorophosphateFluorophosphate pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Regular fluoride toothpaste containing 0.76% sodium monofluorophosphate.

06

What researchers measure

Primary outcomes

  1. Mean Bleeding Index (BI) at Week 12

    The BI assesses the number of bleeding points elicited on probing as a measure of gingival condition. BI will be assessed on the facial and lingual gingival surfaces of each scorable tooth using a probe. The probe will be gently inserted into the gingival crevice to a depth of approximately 1 millimeter (mm) and then run around the tooth gently stretching the epithelium while sweeping from interproximal to interproximal along the sulcular epithelium. Gingival bleeding will be scored on a 3-points scale with scores ranging from 0 to 2, where 0=Absence of bleeding on probing, 1=Bleeding observed within 30 seconds of probing, 2=Bleeding observed immediately on probing. Mean BI will be calculated by taking the average over all tooth sites assessed for a participant. Lower score indicates improvement in the symptoms.

    Time frame: Week 12

Secondary outcomes

  1. Mean BI at Week 6

    The BI assesses the number of bleeding points elicited on probing as a measure of gingival condition. BI will be assessed on the facial and lingual gingival surfaces of each scorable tooth using a probe. The probe will be gently inserted into the gingival crevice to a depth of approximately 1 mm and then run around the tooth gently stretching the epithelium while sweeping from interproximal to interproximal along the sulcular epithelium. Gingival bleeding will be scored on a 3-points scale with scores ranging from 0 to 2, where 0=Absence of bleeding on probing, 1=Bleeding observed within 30 seconds of probing, 2=Bleeding observed immediately on probing. Mean BI will be calculated by taking the average over all tooth sites assessed for a participant. Lower score indicates improvement in the symptoms.

    Time frame: Week 6

  2. Mean Number of Bleeding Sites (NBS) at Weeks 6 and 12

    The NBS elicited on probing will be assessed using the BI assessment. Bleeding will be assessed on the facial and lingual gingival surfaces of each scorable tooth. The probe will be gently inserted into the gingival crevice to a depth of approximately 1 mm and then run around the tooth gently stretching the epithelium while sweeping from interproximal to interproximal along the sulcular epithelium. The NBS for each participant will be calculated as the number of tooth sites with bleeding observed immediately on probing or within 30 seconds of probing.

    Time frame: Week 6 and Week 12

  3. Mean Modified Gingival Index (MGI) at Weeks 6 and 12

    The MGI is a non-invasive assessment which focuses on the visual symptoms of gingivitis (redness, texture, edema). MGI will be assessed for all evaluable surfaces of the facial and lingual/palatal gingiva, four sites per tooth and will be scored on a 5-point scale ranging from 0 to 4, where 0 = Absence of inflammation, 1= Mild inflammation: slight change in color, little change in texture of any portion of the marginal or papillary gingival unit, 2=Mild inflammation: criteria as \[1\] but involving the entire marginal or papillary gingival unit, 3=Moderate inflammation: glazing, redness, edema, and/or hypertrophy of the marginal or papillary gingival unit, 4=Severe inflammation: marked redness, edema and/or hypertrophy of the marginal or papillary gingival unit, spontaneous bleeding, congestion, or ulceration. Lower score indicates improvement in the symptoms.

    Time frame: Week 6 and Week 12

  4. Mean Overall Turesky Plaque Index (TPI) at Weeks 6 and 12

    The TPI is a non-invasive assessment of supra-gingival plaque accumulation. TPI will be assessed on the facial and lingual surfaces of each scorable tooth. Dental plaque will first be disclosed with a plaque disclosing solution and disclosed plaque will be scored using a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin continuous band of plaque (up to 1 mm) at the cervical margin, 3=Band of plaque wider than 1 mm but covering less than (\<) 1/3 of the tooth surface, 4=Plaque covering greater than or equal to (\>=) 1/3 but \< 2/3 of the tooth surface, 5=Plaque covering \>= 2/3 of the tooth surface. Lower score indicates improvement in the symptoms.

    Time frame: Week 6 and Week 12

  5. Mean Interproximal TPI at Weeks 6 and 12

    The TPI is a non-invasive assessment of supra-gingival plaque accumulation. TPI will be assessed on the facial and lingual surfaces of each scorable tooth. Dental plaque will first be disclosed with a plaque disclosing solution and disclosed plaque will be scored using a 6-point scale ranging from 0 to 5, where 0=No plaque, 1=Separate flecks of plaque at the cervical margin, 2=Thin continuous band of plaque (up to 1 mm) at the cervical margin, 3=Band of plaque wider than 1 mm but covering \< 1/3 of the tooth surface, 4=Plaque covering \>= 1/3 but \< 2/3 of the tooth surface, 5=Plaque covering \>= 2/3 of the tooth surface. Lower score indicates improvement in the symptoms.

    Time frame: Week 6 and Week 12

  6. Change from Baseline in Salivary Tin Concentration Pre- and Post-brushing at Weeks 6 and 12

    Unstimulated saliva samples will be collected from participants pre- and post-brushing. The samples will be analyzed for tin concentration to investigate the retention of the stannous \[tin(II)\] ion within the oral cavity. Change from baseline in salivary tin concentration at indicated timepoints will be reported.

    Time frame: Baseline, Week 6 and Week 12: Pre-brushing and at 15, 30, 60, 120 minutes post-brushing

  7. Area Under the Curve (AUC) of Salivary Tin Concentration Post-brushing at Baseline, Weeks 6 and 12

    Unstimulated saliva samples will be collected from participants pre- and post-brushing for the analysis of salivary tin concentration. The AUC \[pre-treatment, t=0 to 120 minutes\] values for the change from baseline in the log10 transformed salivary tin concentrations versus (vs) time will be reported.

    Time frame: Baseline, Week 6 and Week 12: Pre-brushing and at 15, 30, 60, 120 minutes post-brushing

  8. Salivary Tin Concentration Pre-brushing at Baseline, Weeks 6 and 12

    Unstimulated saliva samples will be collected from participants pre- and post-brushing. The samples will be analyzed for tin concentration to investigate the retention of the stannous \[tin(II)\] ion within the oral cavity. Salivary tin concentration at the indicated timepoints will be reported.

    Time frame: Baseline, Week 6 and Week 12

07

Study locations

1 site
  • All Sum Research
    Mississauga, Ontario L5N 6J2, Canada
08

References and documents

Individual participant data

Plan to share: Yes — Anonymized individual participant data and study documents can be requested for further research from ww.clinical-trial-register@haleon.com

Supporting information: Study protocol, Statistical analysis plan, Informed consent form

Time frame: IPD will be made available within 6 months of publishing the results of the primary endpoints, key secondary endpoints and safety data of the study.

Access criteria: Access is provided after a research proposal is submitted and has received approval from the Independent Review Panel and after a Data Sharing Agreement is in place. Access is provided for an initial period of 12 months, but an extension can be granted, when justified, for up to another 12 months.

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2025 to primary completion in Dec 2025, 3 months.

Of 45 industry-sponsored interventional studies with no phase under Dental Plaque, half reached primary completion within 2 months of starting (the median), counting those still running; a quarter within 1 and three quarters within 8. This study's 3 months is above that.

Counting every sponsor, half of 179 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 4, 2025
First posted
Sep 11, 2025
StartActual
Sep 9, 2025
Primary completionActual
Dec 23, 2025
CompletionActual
Dec 23, 2025
Last update
Jan 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 21, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07169188
Lead sponsor
HALEON
Responsible party
Sponsor
First posted
Sep 11, 2025
Start date
Sep 9, 2025
Primary completion
Dec 23, 2025
Completion
Dec 23, 2025
Last update
Jan 21, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion